BNTC vs. ELVN, GPCR, BGM, PRAX, ARDX, AVDL, SANA, DYN, AKBA, and COLL
Should you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include Enliven Therapeutics (ELVN), Structure Therapeutics (GPCR), BGM Group (BGM), Praxis Precision Medicines (PRAX), Ardelyx (ARDX), Avadel Pharmaceuticals (AVDL), Sana Biotechnology (SANA), Dyne Therapeutics (DYN), Akebia Therapeutics (AKBA), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry.
Benitec Biopharma vs. Its Competitors
Benitec Biopharma (NASDAQ:BNTC) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.
52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 1.3% of Benitec Biopharma shares are owned by insiders. Comparatively, 25.9% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Enliven Therapeutics is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.
Enliven Therapeutics' return on equity of -31.84% beat Benitec Biopharma's return on equity.
In the previous week, Enliven Therapeutics had 7 more articles in the media than Benitec Biopharma. MarketBeat recorded 9 mentions for Enliven Therapeutics and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 0.83 beat Enliven Therapeutics' score of 0.54 indicating that Benitec Biopharma is being referred to more favorably in the media.
Benitec Biopharma presently has a consensus price target of $26.00, indicating a potential upside of 132.56%. Enliven Therapeutics has a consensus price target of $41.20, indicating a potential upside of 94.34%. Given Benitec Biopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Benitec Biopharma is more favorable than Enliven Therapeutics.
Benitec Biopharma has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.
Summary
Benitec Biopharma beats Enliven Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Benitec Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Benitec Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:BNTC) was last updated on 7/25/2025 by MarketBeat.com Staff
Free BNTC Stock Alerts